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Aim: To direct precursor cells toward the osteoblastic lineage, by using an intracellular 
nanocarrier releasing dexamethasone. Materials & methods: Biodegradable gelatin-
based micelles entrapped dexamethasone (dex-micelles). Internalization efficiency 
and biocompatibility of dex-micelles and their potency for in vitro osteogenic 
differentiation and in vivo bone regeneration were assessed. Results: Dex-micelles 
were internalized by rat bone marrow mesenchymal stem cells and demonstrated a 
pH-responsive release profile and an enhancement of 2D and 3D in vitro osteogenic 
differentiation. In vivo implantation of gelatin scaffolds seeded with rat bone marrow 
mesenchymal stem cells precultured for 24 h with dex-micelles promoted a significant 
enhancement of de novo bone formation in a rat ulna defect, in a dose-dependent 
manner. Conclusion: The proposed intracellular delivery system is a powerful tool to 
promote bone regeneration.
Keywords: bone regeneration • intracellular delivery • mesenchymal stem cell • micelle 
• nanoparticle • tissue engineering
Bone marrow-derived mesenchymal stem 
cells (BMSCs) have been widely investigated 
and their osteogenic differentiation poten-
tial and bone regeneration capability in both 
animal [1,2] and human models [3–5] has been 
consistently demonstrated. The osteogenic 
differentiation of BMSCs can be induced by 
soluble factors such as dexamethasone (dex), 
typically present in the osteogenic media 
cocktail used for in vitro cultures [6].
Dex is a non-water-soluble synthetic glu-
cocorticosteroid that can induce bone for-
mation through the triggering of a distinct 
set of pathways, including chemokine and 
calcium signaling [7,8]. The stimulatory role 
of dex has been reported at early stages of 
osteogenic differentiation [7,9–10] but also at 
late stages of differentiation, directing cells 
toward terminal maturation through the 
formation of mineralization nodules [11,12]. 
Dex acts through the modulation of nuclear 
steroid receptors [7], initiating transduction 
mechanisms which ultimately will lead to 
bone formation. It is described in the litera-
ture that dex regulates Runx2 via FHL2/β-
catenin-mediated transcriptional activa-
tion [13], via activation of TAZ [14] and via 
activation of MKP-1 [10]. Dex has also been 
shown to invariably increase the propor-
tion of cells expressing alkaline phosphatase 
(ALP), an early osteogenic cell marker [15]. 
In summary, dex regulation depends on the 
degree of cellular differentiation, the donor 
species, dosage, dose duration and dosing 
regimen [8,16].
Cell engineering and tissue engineering 
have benefited from the development of novel 
strategies that can stimulate and control cell 
functions both in vitro and in vivo [17,18]. 
One possible approach could be through the 
use of drug delivery systems promoting the 
enhancement of cell proliferation and differ-
entiation and the production of extracellular 
matrix (ECM) [19]. The design of novel nano-
materials, such as polymeric micelles, to act 
as carriers for controlled release is one of the 
various strategies applied to overcome this 
challenge [20]. Polymeric micelles are nano-
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sized supramolecular constructs formed from the self 
assembly of amphiphilic copolymers in aqueous envi-
ronments with the ability to carry and to deliver hydro-
phobic drugs [21]. These micelles can be tailored for 
intracellular drug release, according with the desired 
experimental design and location of the specific drug 
receptors [22].
The internalization of the nanoparticles by the cells 
allows the modulation of the activity of intracellular 
receptors such as those described for corticosteroids [23]. 
Previous studies [12,24] reported the delivery of dex from 
polymeric carriers, resulting in an enhancement of 
osteogenesis. However, the majority focused on an extra-
cellular delivery of the drug with few exceptions, such as 
the work of Oliveira et al. [16,25], which has showed the 
potency of intracellular release of dex in order to further 
enhance osteogenic differentiation of BMSCs.
In this work we propose the application of a gela-
tin-based micelle system for entrapment and intracel-
lular release of dex. The gelatin polymer chain was 
grafted with lactic acid oligomers in order to create a 
hybrid amphiphilic, able to solubilize dex in an aque-
ous environment (dex-micelles). We hypothesize that 
the internalization of the drug-loaded micelles might 
enhance the in vivo osteogenic potential of the trans-
planted rat BMSCs (rBMSCs), thus avoiding the with-
drawal of dex post in vitro preculture and reducing the 
preculture period.
The specific aims of this study were threefold: 
to assess the potential of gelatin-based micelles to 
be used as a carrier for the intracellular delivery of 
dex (Supplementary Figure 1A; please see online at 
http://www.futuremedicine.com/doi/full/10.2217/
NNM.15.11); to evaluate the effect of the dex-micelles 
internalization on the in vitro osteogenic differentia-
tion of a rat preosteoblastic cell line (MC3T3-E1) and 
rBMSCs (Supplementary Figure 1B); to assess the abil-
ity of gelatin scaffold constructs seeded with rBM-
SCs precultured with the dex-micelles to heal criti-
cal-sized bone defects, using a rat ulna defect model 
(Supplementary Figure 1C). Healing rates were evalu-
ated my measuring new bone formation within the 
defect using radiological, micro-CT, histological and 
immunohistochemistry techniques.
Materials & methods
Materials
A gelatin sample prepared by an acidic treatment of 
porcine skin collagen (isoelectric point [IEP] = 9.0) was 
kindly supplied by Nitta Gelatin, Inc. (Osaka, Japan). 
Disuccinimidyl carbonate (DSC) and 4-dimethyl-
aminopyridine (DMAP) were obtained from Nacalai 
Tesque, Inc., Kyoto, Japan. Glutaraldehyde (GA), gly-
cine, DMSO and other chemicals were obtained from 
Wako Pure Chemical Industries Ltd, Osaka, Japan 
and used without further purification.
Synthesis of l-lactic acid oligomer-grafted 
gelatin
l-lactic acid oligomer (LA
o
) with an average molecu-
lar weight of 1000 D was synthesized from l-lactide 
monomer by the ring-opening polymerization as 
reported in a previous study [26]. Briefly, l-lactic acid 
(3 × 10-5 mol) was dissolved in 15 ml DMSO while 
DSC (9 × 10-5 mol) and DMAP (9 × 10-5 mol) were 
dissolved in 2.5 ml of DMSO. The solution was mixed 
to allow the reaction for 3 h under stirring at room 
temperature to activate the hydroxyl groups of LA
o
. 
The solution of activated oligomer was slowly added 
to gelatin (IEP = 5) solution in DMSO (33 mg/ml) 
and the mixture was stirred overnight at room tem-
perature to promote the grafting of LA
o
 to gelatin. The 
product solution was dialyzed against double distilled 
water with a dialysis tube (molecular weight cut off 
= 12,000–14,000) for 72 h at room temperature, fol-
lowed by freeze drying to obtain the LA
o
-grafted gela-
tin. The ratio of LA
o
 grafted to the amino groups of 
gelatin determined by the conventional fluorescamine 
assay was 3.1 ± 0.8 mol/mol gelatin.
Preparation of dex-micelles
LA
o
-grafted gelatin solution (1 mg/ml) in DMSO 
and a dex solution (1.0 mg/ml) in DMSO were pre-
pared. The dex solution (15 ml) was added to the LA
o
-
grafted gelatin solution (30 ml), followed by 3 h stir-
ring at room temperature. The reaction mixture was 
dialyzed with a dialysis tube (molecular weight cut off 
= 1000 D) against double distilled water for 72 h at 
room temperature. The dialysate obtained was centri-
fuged (8000 rpm, 10 min, 4°C) to remove water-insol-
uble dex, and freeze dried to obtain the dex water solu-
bilized by LA
o
-grafted gelatin micelles (dex-micelles). 
In order to measure the amount of dex incorporated 
into the dex-micelles, the freeze-dried dex-micelles 
were dissolved in 100 vol% ethanol. The solution was 
sonicated for several cycles and centrifuged at 5000 g 
for 10 min. The supernatant was quantified in a HPLC 
(LC-20AT, Shimadzu, Japan) run in a solution com-
posed by sample/acetonitrile/acetate buffer/acetic 
acid (50/25/24/1 vol%). An analytical column (TSK-
gel ODS-100V 5um, TOSOH, Japan) was used and 
the retention time for dex was approximately 4 min. 
Dex concentration was determined from the standard 
curve prepared with the ethanol containing various 
amounts of dex and dispersed in the same running 
solution of sample/acetonitrile/acetate buffer/acetic 
acid (50/25/24/1 vol%). The drug loading achieved 
was of 15 ng dex per μg of dex-micelles.
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Morphological characterization of the 
dex-micelles
The morphological analysis of the developed micelles 
was performed by atomic force microscopy (AFM). A 
drop of dex-micelles suspension of about 0.001% (w/v) 
was placed on a silicon wafer square (10 × 10 mm) and 
AFM measurements were performed using a Multi-
Mode STM Microscope controlled by the NanoScope 
III from Digital Instruments system operating in the 
tapping mode at a frequency of 1 Hz.
Size & surface charge measurements of 
dex-micelles
The size and zeta potential of the dex-micelles were mea-
sured by photon correlation spectroscopy and laser Dop-
pler anemometry, respectively, using a Malvern Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK). The 
size analysis was performed at 25°C with a detection 
angle of 90° and the zeta potential was carried under an 
electric field strength of 100 V/cm. The measurements 
were performed with the dex-micelles dispersed in phos-
phate-buffered saline (PBS; pH 7.4) and citrate buffer 
(pH 4.0). Each sample was diluted to the appropriate 
concentration with filtrated distilled water (0.22 μm).
In vitro dex release studies
The release of dex was determined by incubating 
dex-micelles (2 μg entrapped dex) in 1 ml of pH 7.4 
phosphate buffer or 1 ml of pH 4.0 citrate buffer, 
with horizontal shaking, at 37°C under sink condi-
tions (100 μg/ml saturation solubility). At appropri-
ate time intervals, the release medium was removed, 
centrifuged for 10 min at 8000 rpm and the superna-
tant was collected, freeze dried and dissolved in etha-
nol. Following a new centrifugation step (8000 rpm, 
10 min, 4°C), the dex amount in the supernatant was 
determined by HPLC analysis following the procedure 
previously described.
Labeling of the dex-micelles with rhodamine B
A 10 mg/ml Rhodamine B (RhD) solution was pre-
pared in anhydrous DMSO, in dark conditions. 
Firstly, a 1 mg/ml dex-micelles solution was prepared 
in a carbonate–bicarbonate coupling buffer of pH 9.2. 
Then 5 μl of the RhD/DMSO solution was added 
per each ml of micelles buffered solution under agita-
tion, at 4°C for 8 h. The Rhd-labeled micelles solution 
was dialyzed against double distilled water in order to 
remove the unlinked RhD for 48 h and the labeled 
micelles were frozen at -80°C and freeze dried.
Isolation & culture of rBMSCs
The rBMSCs were isolated from the bone shaft of 
femurs of 3-week-old Fischer 344 rats according to the 
procedure reported previously [27]. Briefly, after cut-
ting off both ends of rat femurs, the bone marrow was 
flushed out with 1 ml of alpha-modified eagle minimal 
essential medium (αMEM). Then, the bone marrow 
cells mixture was cultured in αMEM supplemented 
with 15 vol% fetal bovine serum, and 100 U/ml penicil-
lin and 100 μg/ml streptomycin at 37°C in a 5% CO
2
 
incubator. The medium was refreshed on the 4th day 
after isolation to remove nonadherent cells and continu-
ously refreshed every 3 days thereafter. The cells of the 
second and third passages at the subconfluent condition 
were used for the following experiments.
Evaluation of micelles internalization by 
MC3T3-E1 cells & rBMSCs
Mouse MC3T3-E1 osteoblast-like cells and rBMSCs 
were cultured with αMEM medium supplemented 
with 10 vol% fetal bovine serum and 100 U/ml 
penicillin/100 μg/ml streptomycin (complete basal 
medium) at 37°C in a 5% CO
2
 incubator until 
reaching confluence. Three different concentrations 
of RhD-labeled micelles were added to the culture 
medium: 6.5, 32.5 and 65 μg per million of cells, des-
ignated as low, medium and high doses of dex-micelles, 
respectively. The cells were incubated for 3, 8 and 24 h 
with the micelles. At each time point, the flasks were 
washed with PBS and the internalization efficiency was 
assessed by fluorescence microscopy and flow cytom-
etry. The mechanism of internalization was assessed by 
incubating rBMSCs with 1 μm colchicine for 24 h in 
the presence of high dose of dex-micelles, followed by 
further analysis through flow cytometry. For the flow 
cytometry analysis, cells were trypsinized and incu-
bated for 5 min with propidium iodide, to distinguish 
dead from viable cells. The cells were then analyzed on 
FACSCanto II flow cytometer (BD Biosciences, Inc., 
MA, USA). Analysis was performed by BD FACSDiva 
software (BD Biosciences, Inc.). Each analysis was 
performed for three samples. The fluorescence images 
were taken with an Apotome, Imager Z1 fluorescence 
microscope (Carl Zeiss, Jena, Germany).
In vitro MC3T3-E1 cell viability & proliferation
MC3T3-E1 cells were cultured in complete basal 
medium at 37°C in a 5% CO
2-
95% air atmospheric 
condition until reaching confluence. A suspension of 
12.500 cells in 500 μl of culture medium was seeded 
onto each well in 24-well culture plates (Corning, 
Inc., MA, USA) and cultured for 1, 5, 7 and 14 days 
with either complete osteogenic medium or osteogenic 
medium without dex. The osteogenic medium was com-
posed by complete basal medium supplemented with 
50 μg/ml ascorbic acid, 10 mM β-glycerophosphate 
and 10-8 M dex. Four different group studies were 
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assessed for each culture medium: low dose of empty 
micelles; high dose of empty micelles; low dose of 
dex-micelles and high dose of dex-micelles.
Cytotoxicity of unloaded and dex-micelles was 
assessed using the Cell Count Reagent SF (Nacalai 
Tesque, Inc., Kyoto, Japan) as a colorimetric indica-
tor for living cells. At each time point, 100 μl of the 
reagent containing WST-8 (5mM) was added to each 
well containing the cells and incubated for 3 h. Absor-
bance of each well was measured at 450 nm using a 
microplate reader. The assay was performed three-times 
independently for each experimental sample.
The number of cells was determined by the fluoro-
metric quantification of cellular DNA. The cell lysates 
in 30 mM sodium citrate-buffered saline solution 
(SSC, pH 7.4) containing 0.2 mg/ml sodium dodecy-
lsulfate at 37°C were mixed for 12 h. The cell lysate 
(100 μl) was mixed with the SSC buffer (400 μl) in a 
glass tube. After mixing with a dye solution (500 μl; 
30 mM SSC, 1 μg/ml Hoechst 33258 dye), the fluo-
rescent intensity of mixed solution was measured in a 
fluorescence spectrometer (F-2000, HITACHI, Tokyo, 
Japan) at the excitation and emission wavelengths of 
355 and 460 nm, respectively. The calibration curve 
between the DNA and cell number was prepared by 
using cell suspensions of known concentration. The 
DNA assay was performed three-times independently 
for each experimental sample.
In vitro 2D osteogenic differentiation
MC3T3-E1 cells were seeded on 24 well culture plates 
by adding 12.500 cells in 500 μl of culture medium 
per well. Cells were either cultured in complete osteo-
genic medium or osteogenic medium without dex up 
to 14 days. Four different group studies resulted from 
adding micelles at the beginning of the culture: low 
dose of empty micelles; high dose of empty micelles; 
low dose of dex-micelles and high dose of dex-micelles.
The activity of ALP of cells cultured in the hydro-
gels for 5, 7 and 14 days was assayed by the conven-
tional p-nitrophenyl phosphate method. The ALP 
activity was normalized by the number of cells, deter-
mined by the fluorometric quantification of cellular 
DNA. The experiment was independently performed 
for three samples per experimental group. For detect-
ing possible ECM mineralization, samples cultured for 
14 days were stained with alizarin red staining. For the 
mineralization assessment, the replacement of empty- 
and dex-micelles was also performed each 3 days, when 
the osteogenic medium was replaced.
Preparation of gelatin hydrogels
Gelatin hydrogels chemically crosslinked with glutar-
aldehyde were prepared according to the method pre-
viously reported [28]. Briefly, 100 μl aqueous solution 
of gelatin with IEP = 9.0 (50 mg/ml) was mixed with 
glutaraldehyde solution at a concentration of 0.16 vol% 
and cast into a polypropylene dish (10 × 10 mm). The 
gelatin crosslinking occurred for the following 12 h at 
4°C. The crosslinked gelatin hydrogels were treated 
with 0.1 M aqueous glycine solution at room tempera-
ture for 2 h to block the residual aldehyde groups of glu-
taraldehyde. Following a three-time washing with dou-
ble-distilled water, the hydrogels were freeze dried and 
cut into the appropriate dimensions (1 × 2 × 6 mm3). 
Before every experiment, the hydrogels were sterilized 
by ethylene oxide.
In vitro 3D osteogenic differentiation
MC3T3-E1 cells were cultured in complete basal 
medium. The medium was refreshed every 3 days and 
cells were trypsinized when reaching 80% confluence 
in the culture flasks. At this point, cells were incubated 
for 24 h with three different dosages of dex-micelles 
(low, medium and high dose), with free-form dex 
(in the concentration of typical osteogenic medium 
10-8 M) and with PBS only, as negative control.
After 24 h of in vitro culture, the flasks were washed 
twice with PBS to remove noninternalized micelles 
and cells were then trypsinized and seeded onto gela-
tin hydrogels. A suspension of 1 million cells/50 μl 
was seeded into each hydrogel for 6 h by the agita-
tion seeding technique reported previously. Further, 
1 ml of the medium was added to each construct and 
static culture in osteogenic medium without dex was 
carried on.
The activity of ALP for cells cultured in the hydro-
gels for 5, 7 and 14 days was quantified as previ-
ously described. The ALP activity was normalized 
by the number of cells, determined by the fluoromet-
ric quantification of cellular DNA. The experiment 
was independently performed for three samples per 
experimental group.
In vivo bone regeneration in a rat ulna 
critical-sized defect
A bone defect model of rat ulna was used to evalu-
ate the bone regeneration induced by implantation 
of hydrogels seeded with rBMSCs precultured with 
dex-micelles or free-form dex and rBMSCs not precul-
tured. Surgery was made for 12-week-old male Fisher 
344 rats (n = 24) under standard sterile conditions 
according to the procedure previously reported [29]. All 
the animal experiments were performed following the 
Institutional Guidance of Kyoto University on Ani-
mal Experimentation and upon approval of the ani-
mal experiment committee of the Institute for frontier 
Medical Science, Kyoto University.
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The constructs implanted consisted of gelatin 
hydrogels seeded with 1 million rBMSCs precul-
tured for 24 h with low, medium and high doses of 
dex-micelles. One additional group study consisted of 
hydrogels seeded with 2 million of rBMSCs precul-
tured with high dose of dex-loaded micelles. Hydrogels 
with precultured cells with free-form dex or PBS alone 
were used as controls. Each rat received the implanta-
tion of two constructs randomly placed in both left 
and right of forearm’s ulna.
Briefly, the rats were anesthetized with an intra-
peritoneal injection of pentobarbital sodium solution 
(35–40 mg/kg bodyweight). After shaving the hair 
and disinfection with 70 vol% ethanol, a longitudinal 
incision was made along the forearm skin of rats. The 
periosteum was incised circumferentially to approach 
to the ulna bone. A critical defect of 6 mm in length 
was then created at the middle position of ulna bone 
using a side-cutting diamond disk and a high-speed 
micromotor under an abundant irrigation with ster-
ile saline solution. The hydrogels were implanted into 
the defects while the periosteum and overlying mus-
cle were repositioned with an absorbable polydioxa-
none suture (Ethicon 7-0, NJ). Then, the wound was 
closed with a nonabsorbable polypropylene suture 
(Ethicon 4-0, NJ).
Evaluation of bone tissue regenerated
The bone tissues regenerated at the defect and subcu-
taneous site, 2 and 4 weeks later, were radiologically 
examined by soft x-ray machine (Hitex-100, Hitachi 
Ltd, Tokyo, Japan) at 56 kV and 2.5 mA for 20 s. Then, 
the samples were kept at 4 wt% paraformaldehyde in 
PBS at 4°C, until further analysis. 3D images of bone 
regenerated in the ulna defects were visualized with 
the CT scans (Skyscan 1072, Belgium). Samples were 
scanned at a resolution of 19.12 μm, energy of 100 kV, 
current of 98 μA and exposure time of 2464 ms. The 
x-ray scans were acquired in high resolution mode. The 
2D images were reconstructed with CT Analyzer (Sky-
scan, Belgium) to produce the 3D images in the region 
of the bone defect. Analysis of new bone volume in the 
defect zone was carried out within a circular region of 
interest with at least 140 tomographic layers. Then, the 
fixed samples were decalcified and included in paraf-
fin. For the histological examination, the 6-μm-thick 
sections were cut at the center of samples and mounted 
in a micro-slide glass, followed by staining with hema-
toxylin and eosin and Masson trichrome to observe 
the cell infiltration, newly formed collagen and new 
bone formation. Immunostaining for collagen type 
I antibody was performed to assess the formation of 
ECM. Antigen retrieval was heat induced in a water 
bath at 96°C for 20 min, with incubation of the slides 
in citrate buffer (pH = 6). The slides were washed 
with PBS and endogenous peroxidase was blocked 
with 0.6% hydrogen peroxide (H
2
O
2
; 31,642, Sigma, 
Germany) in methanol (32,213, Sigma, Germany), at 
room temperature for 30 min. R.T.U. Vectastain® Uni-
versal Elite ABC Kit (Vector, VCPK-7200) was used 
for antibody incubation, according to the instructions 
of the manufacturer. Briefly, sections were incubated 
with collagen I antibody (rabbit anti-type I collagen 
ab292, Abcam, UK) overnight at 4°C, in a humidi-
fied atmosphere. Control sections were incubated with 
3% bovine serum albumin in PBS. After washing 
with PBS, antibody detection was revealed by using 
the Peroxidase Substrate Kit DAB (Vector, VCSK-
4100). Slides were washed in water for 5 min and then 
counterstained with Harris’ hematoxylin for nuclear 
contrast. The slides were then mounted using Micros-
copy Entellan (Merck, NJ, USA) for observation 
under a light microscope. All images were obtained 
using a light microscope (Zeiss HAL 100/HBO 100; 
Axiocam MRc5).
Statistical analysis
All the experiments were performed with at least 
three replicates. Results are expressed as mean ± stan-
dard deviation. Differences between the experimental 
results were analyzed using the one-way analysis of 
variance, with the Bonferroni’s multiple comparison 
test, defined with a statistical significance as p < 0.05.
Results
Physico-chemical characterization of the empty 
& dex-micelles
Micelles presented a spherical morphology, as it can 
be observed in the AFM image (Figure 1A). Dynamic 
light scattering showed that the dex-micelles have a 
mean size of 352 nm at physiological pH and a slightly 
negative zeta potential (Figure 1B). When dispersed in 
an acidic buffer, the size of the micelles increased sig-
nificantly up to 595 nm and zeta potential increased 
to slightly positive values. The pH of citrate buffer 
is similar to the IEP of gelatin, which contributes to 
the reduced surface charge of the micelles. HPLC 
analysis showed no free nanoprecipitated drug in the 
dex-micelles suspension as no distinct peak could be 
detected for free-form dex.
In vitro cumulative dex release studies were also per-
formed in acidic and neutral conditions (Figure 1C & D). 
At pH 7.4, the micelles showed a controlled dex release 
profile during the tested 7 days, releasing approxi-
mately 0.8 μg of the corticoid, which corresponds to 
40% of the initial amount of drug. However, when the 
micelles were dispersed in acidic medium, the release 
was much faster and all drug was released upon 5 days.
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Figure 1. Characterization of the dex-micelles. (A) Morphological characterization by AFM; (B) DLS analysis of the 
dex-micelles dispersed in neutral and acidic buffers. Parameters such as particle size, PDI and zeta potential were 
measured. (C & D) Cumulative in vitro dex release from the drug-loaded micelles in an acidic (-♦-) and neutral (-▪-) 
buffers presented in total mass (C) and% (D). 
AFM: Atomic force microscopy; DLS: Dynamic light scattering; PDI: Particle size distribution index.
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Assessment of internalization efficiency of  
dex-micelles
The efficiency of fluorescence labeling was assessed and 
the conjugation of rhodamine to the micelles proved to 
be effective for the period in which the internalization 
of the micelles was analyzed (24 h). The high density 
of positive cells for fluorescent-labeled micelles was 
observed for both cell types, in particular for MC3T3-
E1 cells (Figure 2). Three doses of dex-micelles, for both 
cell types and for three different incubation periods 
were tested. For MC3T3-E1 cells, after only 4 h, the 
levels of internalization almost peaked and remained 
around 100% for the remaining incubation periods.
In the case of rBMSCs, the group studies incubated 
with high doses of fluorescent-labeled dex-micelles 
showed a statistically significant (p < 0.05) higher 
number of positive cells for internalization after 4 and 
8 h of incubation, with values around 85%. After 
24 h of incubation with micelles, the cultures contain-
ing medium and high doses of dex-micelles showed 
approximately 90% of positive cells while the culture 
with low concentration of dex-micelles showed a statis-
tically significant lower amount of positive cells of only 
65% after 24 h. In addition, Figure 2B shows the fluo-
rescence microscopy images of MC3T3-E1 cells cul-
tured with high dose of Rhd-labeled micelles for 8 and 
24 h. Micelles are clearly detected in the cytoplasma 
of the cells, mostly surrounding the cell nucleus. Very 
few cells were detected presenting absence of internal-
ized micelles, indicating a homogeneous uptake of the 
nanoparticles by the cell population. Results shown in 
Figure 2C demonstrate a significant decrease on micelle 
internalization when the cultures were incubated with 
colchicine, an endocytosis-blocking agent. These 
micelles were shown not to be uptaken by physico-
chemical permeation through the phospholipic bilayer. 
Exposure of rBMSCs to colchicine seems to prevent 
the formation of vesicular structures, suggesting that 
endocytosis is one of the most important mechanisms 
of internalization for these nanocarriers.
In vitro biological assessment of dex-micelles
The incubation of dex-micelles with MC3T3-E1 cells 
decreased cell proliferation and enhanced in vitro 
osteogenic differentiation in a dose-dependent man-
ner. In Figure 3A, it is possible to observe that the 
addition of empty gelatin micelles did not induce a 
negative effect on the viability of the cells in both 
culture mediums in presence or absence of dex. The 
same pattern was observed for the proliferation studies 
www.futuremedicine.com 1713
Figure 2. Internalization efficiency of dex-micelles by MC3T3-E1 cells and rat bone marrow-derived mesenchymal 
stem cells. (A) Flow cytometry analysis of both cell types incubated for 4, 8 and 24 h with three different doses 
of dex-micelles: low, medium and high doses. *p < 0.05. (B) Representative images of fluorescence microscopy 
analysis of MC3T3-E1 cells incubated for 8 and 24 h with low dose of dex-micelles, correspondent to approximately 
100% of positive cells. Scale bar represents 10 μm. (C) Flow cytometry analysis of rBMSCs incubated for 24 h with 
high dose of dex-micelles in presence or absence of colchicine.  
*p < 0.05. 
rBMSC: Rat bone marrow-derived mesenchymal stem cell.
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(Figure 3B) up to 5 days of culture and empty micelles 
showed a similar proliferation profile to osteogenic 
medium.
At day 7 and 14, some differences could be observed 
but in general it can be said that the gelatin micelles 
herein proposed do not harm cell proliferation. How-
ever, when cells were loaded with different dosages of 
dex-micelles (low and high), a significant decrease of 
cell viability was observed, specifically at days 1, 5 and 
7 for all groups and also at day 14 for the cultures with 
complete osteogenic medium. At day 14, this nega-
tive effect was recovered for the cultures in osteogenic 
medium without dex and the MC3T3-E1 cultures in 
presence of dex-micelles show similar viability to the 
controls. Low and high doses of dex-micelles promoted 
a statistically significant decrease (p < 0.05) on cell 
proliferation at days 5 and 7 when compared with the 
controls with culture medium only and supplemented 
with empty micelles. At day 14, this difference is not 
clear and although there are some individual differ-
ences between different group studies, it seems clear 
that the cells cultured in the presence of dex-micelles 
recovered their proliferative character.
Supplementary Figure 2A shows the ALP quanti-
fication up to 14 days of MC3T3-E1 cells cultured 
in monolayer with complete osteogenic medium 
and osteogenic medium without dex. Cells were 
also supplemented with low and high doses of 
dex-micelles and it was possible to observe that at 
day 7 and 14 the ALP activity was significantly 
enhanced (p < 0.05) for the supplemented condi-
tions. Supplementary Figure 2B presents the alizarin 
red staining for detection of mineralization nodules 
after 14 days of culture under osteogenic stimula-
tion. Despite the addition of supplements such as 
ascorbic acid and β-glycerophosphate, osteogenic 
medium without dex was not sufficient to promote 
mineralization and the addition of empty micelles 
(low and high doses) did not change this outcome. 
However, when dex-micelles were added to the cul-
ture medium without dex, mineralization was clearly 
enhanced with the formation of several nodules for 
the group studies where dex-micelles were just added 
once in the beginning of culture. When fresh dex-
micelles were added each time the culture medium 
was replaced, the mineralization enhancement was 
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Figure 3.  Evaluation of viability (A) and proliferation (B) of MC3T3-E1 cells cultured 2D in vitro up to 14 days, 
under osteogenic stimulation. Cells were cultured in complete osteogenic medium in presence (+) or absence (-) 
of free-form dexamethasone. Two dosages of empty and dex-micelles were assessed – low and high doses. 
*p < 0.05.
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less robust and for the high dosage of dex-micelles, 
it did not even occur. For the MC3T3-E1 cultures 
in complete osteogenic medium, the addition of 
dex-micelles significantly decreased the formation 
of mineralized nodules, both for the group stud-
ies where dex-micelles were replaced or not during 
culture.
Supplementary Figure 2C reports the ALP quantifi-
cation of MC3T3-E1 cells seeded onto gelatin hydro-
gels and cultured up to 14 days in vitro with osteogenic 
medium without dex. These hydrogels presented a typ-
ical porous and interconnected internal structure with 
pores sized 100–400 μm (see SEM image enclosed in 
Supplementary Figure 1), which are optimal for bone 
progenitor cells. Before seeding onto the scaffolds, cells 
were precultured for 24 h with three dosages of dex-
micelles (low, medium and high) and PBS only as con-
trol. A statistically significant (p < 0.05) enhancement 
of ALP activity of cells precultured with dex-micelles 
was observed at day 14. Moreover, the increment of 
ALP activity promoted by the cells precultured with 
high dose of dex-micelles was significantly stronger 
(p < 0.05) than the remaining dosages of drug-loaded 
carriers.
The role of dex dosage can be observed in 
Supplementary Figure 2B in two different scenarios. 
When the dex-micelles were added to 2D cultures in 
complete osteogenic medium (with dex), mineraliza-
tion was decreased in comparison with the controls; 
when the dex-micelles were added to 2D cultures 
in osteogenic medium without dex, mineralization 
was strongly enhanced in comparison with the con-
trols; however when fresh dex-micelles were added to 
the cultures each time the medium was changed, a 
decrease on the mineralization level was observed for 
the high-dose condition.
In vivo assessment of bone regeneration in an 
ulna defect model
Figure 4A & B show the soft x-ray and micro-CT images 
of bone regenerated in vivo in the ulna defect, respec-
tively. Figure 4C presents quantitative data regarding 
new bone volume formation in vivo.
New bone formation could be observed in the 
defects implanted with the hydrogels incorporating 
transplanted cells internalizing dex-micelles. The 
hydrogels seeded with nontreated rBMSCs did not 
promote bone regeneration in the defect, as well as 
the cells precultured with free form dex, as observed 
in Figure 4A & B. After 2 and 4 weeks of implanta-
tion, it was possible to observe a pattern of more new 
bone formation when cells were incubated with higher 
amounts of dex-micelles. The use of a higher amount 
of cells also enhanced bone formation as observed for 
the hydrogels seeded with 2 million rBMSCs preincu-
bated with high dose of dex-micelles (Figure 4A & B). 
In the control defects, the cut ends of the ulnas were 
consistently rounded off with a small amount of new 
bone and bridging of the defects was never observed. 
In contrast, x-ray and micro-CT images showed pro-
gressive infiltration of mineralized tissue into scaffold-
treated defects seeded with cells internalizing dex-
micelles, almost completely bridging the defect after 
4 weeks.
There was a significant increase in new bone volume 
with time within treatment groups, as illustrated by 
Figure 4C. The ulna defects treated with gelatin scaf-
folds seeded with rBMSCs internalizing dex-micelles 
showed a significant increase (p < 0.05) in bone vol-
ume at 2 and 4 weeks of implantation time. Moreover, 
this tendency was stronger for higher concentrations 
of micelles incubated with the cells, confirming the 
results observed by x-ray and micro-CT. The implan-
www.futuremedicine.com 1715
Figure 4. Quantification of new bone tissue formed after 2 and 4 weeks of implantation in a rat ulna critical sized defect of the 
gelatin constructs seeded with different concentrations of rat bone marrow-derived mesenchymal stem cells precultured for 24 h 
with low (0.1 μg per million of cells), medium (0.5 μg per million of cells) and high doses (1 μg per million of cells) of dex-micelles, 
with free-form dex (0.1 μg per million of cells) and phosphate-buffered saline only as negative controls. The characterization was 
performed by (A) x-ray; (B) micro-CT and (C) new bone volume measurements, obtained from the micro-CT technique. 
*p < 0.05. 
rBMSC: Rat bone marrow-derived mesenchymal stem cell.
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tation of gelatin scaffolds with nontreated rBMSCs or 
rBMSCs precultured with free-form dex did not sig-
nificantly increase bone volume at either time point. 
All of the defects bridged by mineralized matrix at 
4 weeks had a similar distribution of slightly lower 
density tissue ingrowth at 2 weeks postimplantation. 
New bone formation was more intense during the first 
2 weeks than the last 2 weeks of implantation time. 
Figure 5 shows the histological data regarding the in 
vivo regeneration of the ulna defect and confirmed 
that the high-density areas seen in the micro-CT scan 
corresponded to areas of newly formed bone. Two 
weeks after implantation, histological sections showed 
new bone formation with osteoblasts and osteo-
cytes in all implants containing rBMSCs internaliz-
ing dex-micelles. After 4 weeks, more extensive bone 
formation was observed for the same groups and the 
implants showed abundant osteocytes with substantial 
ECM. The gelatin scaffolds seeded with nontreated 
rBMSCs or precultured with free form dex exhibit 
fibrous tissue invasion with no evidence of bone for-
mation, demonstrating the critical size of the defect. 
Small areas of the unfilled defect were still occupied by 
the remaining implanted gelatin hydrogels (Figure 5). 
Detailed histological characterization can be observed 
in Supplementary Figure 4.
Figure 5C & D (4 weeks implantation time) show a 
more organized tissue structure than Figure 5A & B 
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Figure 5. Histological cross-sections of explants from 
rat ulna defects regenerated with gelatin hydrogels 
seeded with rat bone marrow-derived mesenchymal 
stem cells precultured for 24 h with low, medium and 
high doses of dex-micelles, with free-form dex and 
phosphate-buffered saline only as negative controls. 
(A) Hematoxylin and eosin and (B) Masson Trichrome, 
both for 2 weeks after implantation; (C) hematoxylin 
and eosin and (D) Masson Trichrome for 4 weeks after 
implantation of the constructs. Embedded images show 
higher magnifications. Scale bar presents 500 μm for 
the main image and 100 μm for the embedded ones.
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(2 weeks implantation time), suggesting the matu-
ration of the new bone tissue being formed and the 
accumulation of ECM. Supplementary Figure 4 shows 
the immunohistochemistry staining images of col-
lagen type I (Figure 5A & C) and negative controls 
(Figure 5B & D) for the in vivo regenerated tissue after 
2 and 4 weeks of implantation time, respectively. Col-
lagen I detection is more evident for higher doses of 
dex-micelles.
Discussion
Previous studies [30,31] demonstrated that the pretreat-
ment of MSCs with dex results in greater bone forma-
tion in vivo. However, in vitro osteogenic differentia-
tion requires an additional culture period of weeks [6] 
and cells may not maintain in vivo the cellular phe-
notype upon withdrawal of dex, since it acts at mul-
tiple stages in the differentiation process [32]. Previ-
ous studies regarding the long-term administration of 
this hormone resulted in the dex-induced bone loss by 
attenuation of osteoblast proliferation, impaired colla-
gen synthesis, increased osteoblast apoptosis and inhi-
bition of osteogenic growth factors [8,10]. Therefore, it 
is desirable to implant nondifferentiated cells, showing 
immunomodulatory properties [33,34], supplied with 
osteoinducer molecules at controlled doses that will 
enhance their potency for osteogenic differentiation 
in situ.
The application of a gelatin-based delivery system 
for a non-water-soluble drug presents several advan-
tages. Gelatin is a biodegradable material and has been 
extensively used for pharmaceutical and medical pur-
poses [26,35]. The material advantages of gelatin are the 
easiness of chemical modification and the commercial 
availability of materials with different physicochemi-
cal properties [26]. The micelles herein developed were 
produced by dialysis through the replacement of the 
organic medium with water.
At pH 4.0, which is close to the IEP of the gela-
tin, dex-micelles exhibited an almost neutral surface 
charge. Negative zeta potential values were recorded 
for pH 7.4, corresponding also to pH values above the 
IEP of gelatin, demonstrating the dependency of the 
surface charge of gelatin micelles on pH. The narrow 
particle size distribution index at physiological pH sug-
gested the narrow size distribution of the dex-micelles 
at pH 7.4. However, when dispersed in acidic buf-
fer, PDI increased significantly, suggesting a possible 
destabilization of the micellar structure. The pH of 
4.0 simulates the acidic environment of the endosomal 
compartment where the dex-micelles are located after 
being internalized by the cells. This system presents 
advantages over previously proposed intracellular 
delivery systems as it allows the incorporation and 
release of molecules without covalent conjugation 
of the drug to the carrier as opposed to dendrimers 
and drug–polymer conjugate nanocarriers. Moreover, 
micelles allow the entrapment of higher amounts of 
drug per nanocarrier, enhancing the efficacy of the 
release system [36].
Dex-micelles could be bound to fluorescent-probe 
rhodamine for tracing purposes. The percentage of 
positive cells internalizing the micelles varied and 
tended to increase with culturing time up until its 
peak time. The most significant mechanism of uptake 
is endocytosis [36] as demonstrated in Figure 2C and the 
micelles, at acidic pH as the acidic and enzymatic envi-
ronmental pH of the endosomal compartment, showed 
a faster release of dex when compared with the release 
in a neutral buffer. The release of physically encapsu-
lated dex from its carrier is dependent on both the rate 
of drug diffusion from micellar core and core degrada-
tion [37]. In the acidic endosomal compartment, gela-
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tin molecules become protonated which enhances the 
repulsive forces in the micellar system, widening the 
mesh sizes of the nanoparticles. Moreover, the acidic 
environment could lead to a faster degradation of the 
carrier.
Three different doses of dex-micelles were used 
during this study. The in vitro 2D studies were per-
formed only with the two extreme concentrations, 
low and high doses, while the studies involving the 
preculture of cells with the dex-micelles for posterior 
seeding onto gelatin hydrogels for in vitro and in vivo 
osteogenic differentiation were performed with low, 
medium and high dosages of dex-micelles. Low dose 
of dex-micelles corresponded to the same concentra-
tion of dex present in osteogenic culture medium 
(10-8 M) while medium and high-represented dex 
concentrations five and tenfold higher, respectively. 
We hypothesize that undesirable cytotoxicity could 
be reduced since the intracellular release at acidic pH 
also follows a relatively controlled profile, avoiding 
bolus delivery of dex.
The effect of dex on cell proliferation has been shown 
to depend on the glucocorticoid concentration and 
osteoprogenitor maturity [8]. Our results provide evi-
dence of the inhibitory effect of dex over cell prolifera-
tion, suggesting that dex acts to direct osteoprogenitor 
cells from a proliferation state to a matrix maturation 
stage. At early time points, continuous exposure to dex 
decreased cell number. These results also showed that 
dex was in fact being released from the carriers because 
the conditions where the cultures were supplemented 
with dex-micelles showed a significant decrease on cell 
viability and proliferation. This inhibitory effect was 
reduced at day 14, which complements the informa-
tion obtained from the dex in vitro release studies. As 
dex is fully released from the dex-micelles in an acidic 
environment after 5 days, cell proliferation was not 
impaired afterward.
The presence of dex-micelles in culture enhanced 
ALP activity in a dose-dependent manner (on SI), 
suggesting stronger osteogenic differentiation of 
MC3T3-E1 cells. This dose-dependent action of dex 
has been previously reported [8,16]. Despite the addi-
tion of osteogenic supplements such as ascorbic acid 
and β-glycerophosphate, our in vitro data demon-
strated that the delivery of dex by the micelles was 
required to enhance the levels of osteogenic differen-
tiation. Ascorbic acid is reported to increase the secre-
tion of collagen I and consequently leading to the 
phosphorylation of ERK1/2 in the MAPK signaling 
pathway and subsequent translocalization of ERK1/2 
to the nucleus, where it binds to Runx2 and induces 
gene expression of osteogenic proteins. On the other 
hand, β-glycerophosphate acts as the source of phos-
phate for hydroxyapatite and on the phoshorylation 
of ERK1/2 [38]. Despite the significant contribution 
of ascorbic acid and β-glycerophosphate for in vitro 
osteogenic differentiation, results from this study 
demonstrate that their supplementation in the cul-
ture medium is not sufficient to trigger a transition 
from a precursor to a fully differentiated osteoblastic 
phenotype.
Gelatin hydrogels have been shown to act as osteo-
conductive biomaterial in vivo [26] and to provide an 
affective template for new bone growth and defect 
healing in this defect model [39]. MC3T3-E1 osteo-
blast-like cells precultured for 24 h with three dosages 
of dex-micelles and seeded onto gelatin hydrogels pre-
sented indication of stronger osteogenic induction by 
the enhancement of ALP activity in vitro. Therefore 
the ability of dex-micelles to enhance osteogenic dif-
ferentiation was kept in a 3D setting with only a 24-h 
preculture supplement.
The orthotopic location in vivo is expected to pro-
vide more accurate outcomes concerning the influ-
ence or local effects of implanted cells or cell scaf-
fold constructs where they were initially designed to 
be functional [40]. The ulna defect is appropriate for 
in vivo tests as it does not require further internal or 
external fixation, which might influence the outcome 
of the experiment. This model, including the specific 
dimensions of the defect (6 mm) was previously vali-
dated, since it was shown to enable a minimal growth 
of bone volume in the defect over time [27]. For the 
in vivo studies described in the present study, hydro-
gel samples were seeded with 1 million of rBMSCs, 
precultured with low, medium and high doses of dex-
micelles. As controls, cell precultures were supple-
mented with PBS only and free-form dex (10-8 M). 
An additional group study was added with a seed-
ing of 2 million cells (precultured with high doses of 
dex-micelles) per scaffold. The selected implantation 
times, 2 and 4 weeks, were chosen based on previ-
ous studies using the same defect model and gela-
tin hydrogels [27,28]. Since an early action of dex was 
expected, due to the natural role of the drug, in vitro 
release profile and general instability of the micelles in 
an acidic environment, the implantation times were 
thought to be adequate.
It was also shown that an in vitro osteogenic induc-
tion of BMSCs prior to the implantation facilitates 
bone formation in the implanted constructs [34]. 
However, it has been stated that the withdrawal 
of dex from the cultures when implanted in vivo 
resulted in an inferior osteogenic differentiation. 
The previous incubation of the cells with the loaded 
micelles permits to program their differentiation to 
the osteoblastic lineage even if they are placed in non-
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osteogenic conditions. Therefore, the preculture of 
osteoprogenitor cells with dex-micelles for 24 h and 
further seeding onto a gelatin construct with implan-
tation in vivo of the construct at day 0 is a feasible 
strategy to promote new bone formation in a critical 
size defect and to overcome a long preimplantation in 
vitro osteogenic induction. The rBMSCs would still 
present their stemness character while internalizing 
an osteoinducer molecule, reducing the preculture 
time and avoiding dex withdrawal after preculture 
while stimulating rBMSCs toward the osteogenic 
phenotype. Moreover, the use of high concentrari-
ons of dex in free form as the ones selected for the 
highest dose of dex-micelles proved to be toxic for 
the rBMSCs, leading to significant decrease of cell 
viability after few hours of incubation with the glu-
cocorticoid. This highlights the potential to use the 
gelatin-based micelles in order to control the delivery 
kinetics of a potent osteoinducer but toxic molecule 
such as dex.
The production of calcium phosphate mineral phase 
detected by x-ray and micro-CT suggests the genera-
tion of a mature osteoblast population, which allows 
the production of osteoid and ECM [7]. The x-rays, 
micro-CT and new bone volume quantifications 
showed a progressive increase of mineralized tissue 
with increasing dosages of dex-micelles. This suggests 
that more dex-micelles were internalized by the cells 
and that they are releasing the drug and promoting the 
formation of new mineralized tissue. The constructs 
seeded with nontreated rBMSCs did not regenerate the 
defect, confirming its critical size. Preculture with free-
form dex also did not promote new bone formation. 
For this group study, rBMSCs were in contact with 
the glucocorticoid only for 24 h and then the drug 
was withdrawn, while the dex-micelles were expected 
to release dex inside the cells up to almost 1 week 
post-in vivo implantation.
In vivo bone regeneration induced by BMSCs 
depends on the presence of a sufficient number of early 
osteoprogenitors on the implant that can proliferate 
and further differentiate into osteoblasts [15]. For this 
reason, the cell number was also evaluated and two 
cell densities were assessed: 1 and 2 million of rBM-
SCs per scaffold. New bone volume was significantly 
higher for the constructs seeded with 2 million rBM-
SCs and a bigger cell population was more effective for 
the formation of new bone tissue.
The therapeutic action of donor MSCs may not be 
solely limited to their direct conversion into osteo-
blasts as they also possess other functionalities such 
as antiapoptotic effects, immunoregulatory functions 
and stimulation of host cell migration [41]. Therefore, 
the implanted MSCs can act as signaling centers for 
the host response to the injury and play a ‘kick-off ’ 
role in attracting other cells from the host by the secre-
tion of paracrine factors and stimulate them to differ-
entiate toward the osteogenic lineage. In the literature 
it is not reported the role of dex as a chemotactic agent 
for host MSCs, which allows us to speculate that the 
corticoid is mainly acting on the osteogenic differen-
tiation of the implanted cells, which then, through 
intercellular mechanisms, induce an enhanced host 
MSCs infiltration within the defect. The clear obser-
vation of the drug concentration pattern on new 
bone formation and the increased regenerated tissue 
in implants with higher cell amount suggest that the 
implanted cells are responsible for the differences 
between the different groups. These results show that 
a longer supply of dex in a regimented manner, as the 
corticoid can be released from the micelles inside the 
cells during the in vivo regeneration, promotes an 
enhancement of new bone formation. However, it 
should be stated that dex can raise the risk of infec-
tion and therefore careful monitoring should be per-
formed in order to avoid infection risks during tissue 
repair procedures.
The results obtained in this study were at least 
comparable to the bone regeneration observed for the 
same model using the delivery of bone morphogenetic 
protein-2 [27], gold standard for the promotion of new 
bone formation. This outcome demonstrates that the 
design of appropriate nanoparticle and cell engineer-
ing strategies can improve some of the limitations 
observed with current delivery systems, which include 
excessive dosages, high cost and inefficient drug 
action. Cell engineering is a powerful tool to manipu-
late cell fate and differentiation and the proposed drug 
delivery mechanism is a promising approach for bone 
regeneration.
Conclusion
In summary, the developed dex-micelles were able to 
be internalized by MC3T3-E1 osteoblast-like cells 
and rBMSCs and to release dex in a pH-dependent 
manner. The drug-loaded micelles promoted the 2D 
in vitro osteogenic differentiation of MC3T3-E1 and 
their preculture with dex-micelles for 24 h prior seed-
ing onto gelatin hydrogels also resulted in enhanced 
osteogenic differentiation. Moreover, when in an 
in vivo setting, the rBMSCs precultured with dex-
micelles for 24 h and seeded onto gelatin hydrogels 
promoted a superior in vivo bone formation due to 
the intracellular release of dex, which enhanced rBM-
SCs osteogenic differentiation in a dose-dependent 
fashion.
This study shows that the combination of cell engi-
neering, nanotechnology and tissue engineering in one 
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strategy is a powerful tool to manipulate cell fate and 
differentiation and the proposed drug delivery mecha-
nism is a promising approach for bone regeneration. 
Moreover, this system has the potential for applica-
tion in cell engineering approaches for other tissues, in 
which the released bioactive agent might modulate the 
cellular behavior through the action on cytoplasmatic 
receptors.
Future perspective
The development of new technologies and the abil-
ity to build up tissue engineering and regenerative 
medicine strategies with higher levels of complexity 
and characterization has been increasingly observed 
for the past decade. The use of targeted nanocarriers 
for drug delivery to preprogram stem cells in order 
to modulate their fate and performance represents a 
promising approach for maximizing the potential of 
these regenerative therapies. Critical considerations 
for the development of improved carriers include 
safety, biocompatibility, stability and the ability to 
transfer therapeutic molecules to the target cells at 
high efficiency.
It is crucial to understand the barriers that need to 
be overcome during the transport process in order to 
develop highly efficient delivery systems. The biologi-
cal fate of nanoparticles in the body is one of the main 
concerns in this field of research and increasing efforts 
have been invested to comprehend the mechanisms of 
internalization and excretion of these carriers from the 
cells, as well as their distribution in the body and affin-
ity for specific tissues. The toxicity assessment is still at 
an early stage of development and inconsistent data are 
reported in the literature due to the lack of standard-
ization of protocols for the assessment of toxicity of 
nanomaterials. Moreover, in order to support smooth 
transition into clinical practice, the ease of large-scale 
manufacture, administration and cost–effectiveness 
must also be considered.
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Executive summary
Production & development of dexamethasone-loaded gelatin micelles
•	 Gelatin micelles presented a pH-dependent release profile of dexamethasone (dex).
•	 The micelles showed the ability to be internalized by different cell types in few hours, with levels of efficiency 
between 65 and 100%.
•	 When blocking the endocytic route, the levels of micelle internalization were significantly reduced, thus 
suggesting endocytosis as one the main mechanisms by which the particles were internalized.
In vitro biological assessment of dexamethasone-loaded gelatin micelles
•	 Exposure of cells to dex-loaded nanocarriers induced an inhibition on cell proliferation, thus demonstrating 
that the drug was indeed being released from the micelles. This effect was time and dose-dependent as at 
later time points, cells were able to recover their proliferative character once dex was fully released from the 
nanoparticles.
•	 Incubation of osteoprogenitor cells with the dex-loaded micelles enhanced alkaline phosphatase production 
and deposition of mineralized matrix.
In vivo biological assessment of dexamethasone-loaded gelatin micelles
•	 Preculture of rat bone marrow stem cells with dex-loaded micelles for 24 h and further seeding of those cells 
onto gelatin hydrogels and consequent implantation in vivo in rat ulna critical size defects resulted in an 
efficient deposition of mineralized tissue up to 4 weeks of implantation.
•	 The extent of regenerated bone was dependent on the dosage of micelles that were preincubated with the 
stem cells, as well as the concentration of stem cells seeded onto the gelatin scaffolds.
•	 Histological analysis revealed that the newly formed tissue already presented high levels of bone extracellular 
matrix organization, unlike the controls with empty micelles or free-form dex, in which only fibrotic tissue 
could be found.
•	 This strategy is a cost-effective and efficient cell engineering approach to induce bone regeneration as by 
tailoring the properties and dosages of the delivery systems, high levels of tissue regeneration were quickly 
achieved.
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